Short communicationAdjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability

- Efficacy and tolerability of EZG/RTG were assessed by class of adjunctive AED.
- Mechanistic classes included sodium or non-sodium channel blockers, or ≥1 of each.
- Mechanistic class of AED did not affect EZG/RTG efficacy or tolerability.

SummaryIntegrated data from three double-blind, randomized, placebo-controlled trials were analyzed to evaluate the efficacy and tolerability of ezogabine (EZG; US adopted name)/retigabine (RTG; international non-proprietary name) when used in combination with ≥1 sodium channel blocking antiepileptic drug (AED), ≥1 non-sodium channel blocking AED, or ≥1 AED from both the sodium channel and non-sodium channel mechanistic groups. Efficacy and tolerability appeared to be similar across all three groups of patients.